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Background: The study goal was to describe etravirine pharmacokinetics during
pregnancy and postpartum in HIV-infected women.
Methods: IMPAACT P1026s and PANNA are on-going, non-randomized, open-label,
parallel-group, multi-center phase-IV prospective studies in HIV-infected pregnant
women. Intensive steady-state 12-h pharmacokinetic profiles were performed from 2nd
trimester through postpartum. Etravirine was measured at two labs using validated ultra
performance liquid chromatography (detection limits: 0.020 and 0.026 mcg/mL).
Results: Fifteen women took etravirine 200mg twice-daily. Etravirine AUC0–12 was
higher in the 3rd trimester compared to paired postpartum data by 34% (median 8.3 vs.
5.3 mcg∗h/mL, p = 0.068). Etravirine apparent oral clearance was significantly lower in
the 3rd trimester of pregnancy compared to paired postpartum data by 52% (median 24
vs. 38 L/h, p = 0.025). The median ratio of cord blood to maternal plasma concentration
at delivery was 0.52 (range: 0.19–4.25) and no perinatal transmission occurred.
Conclusion: Etravirine apparent oral clearance is reduced and exposure increased
during the third trimester of pregnancy. Based on prior dose-ranging and safety data,
no dose adjustment is necessary for maternal health but the effects of etravirine in utero
are unknown. Maternal health and infant outcomes should be closely monitored until
further infant safety data are available.
Clinical Trial registration: The IMPAACT protocol P1026s and PANNA study are
registered at ClinicalTrials.gov under NCT00042289 and NCT00825929.
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INTRODUCTION
In 2013, 16 million women were living with human
immunodeficiency virus (HIV) infection, 1.3–1.6 million
of these women were pregnant and perinatal transmission
accounted for an estimated 90% of newly HIV-infected children
(Prevention of mother-to-child transmission, 2015). The use of
combination antiretroviral therapy (ART) can reduce the risk of
perinatal transmission from ≥20 to <1% while also protecting
the health and survival of the mother (HIV among pregnant
women, infants, and children in the United States, 2012). Current
National Institute of Health (NIH) guidelines at aidsinfo.nih.gov
and the World Health Organization (WHO) recommend
combination ART for all pregnant women regardless of CD4
count (Panel on Treatment of HIV-Infected Pregnant Women
and Prevention of Perinatal Transmission, 2014; Prevention
of mother-to-child transmission, 2015). Combination ART
coverage for pregnant women in low to middle income countries
has been steadily rising from 47% in 2009, to 56% in 2011, and
67% in 2013 (HIV/AIDS data and statistics, 2013).
Appropriate drug therapy in pregnancy is complicated by
the many physiological changes that impact drug absorption,
distribution, metabolism, and excretion. These changes include
increases in gastrointestinal transit time, gastric pH, total body
water, and fat which impact drug absorption and distribution.
Increases in several hormones can induce metabolic pathways,
compete for protein binding and compete for metabolic enzymes
impacting free drug concentration and metabolism. Excretion
is affected by increased hepatic plasma flow, renal plasma flow,
and increased glomerular filtration rate. Further impacts to drug
disposition occur due to decreases in gastric acid secretions,
decreases in plasma proteins via dilution, nausea, and vomiting
(Mirochnick and Capparelli, 2004). Pregnant women are a largely
unstudied population in clinical trials and many antiretrovirals
are initially recommended at standard adult doses due to limited
or absent pharmacokinetic data during pregnancy.
Subtherapeutic antiretroviral exposure during pregnancy can
lead to increased perinatal transmission, development of drug
resistant mutations, and disease progression while elevations
in antiretroviral exposure can lead to toxicity. Antiretroviral
exposure across the placenta is crucial to the fetus, with the
potential to provide prophylaxis against HIV infection or cause
fetal toxicity (Mirochnick et al., 2010). Previous pharmacokinetic
studies have typically shown reduced exposure of antiretroviral
drugs during pregnancy with the greatest reductions seen
with boosted protease inhibitors. Among first generation
non-nucleoside reverse transcriptase inhibitors (NNRTIs)
chronically administered throughout pregnancy, efavirenz
plasma concentrations are reduced and nevirapine plasma
concentrations are not significantly different during pregnancy.
Etravirine and rilpivirine, second generation NNRTIs, lack
sufficient pharmacokinetic data in pregnancy (Colbers et al.,
2014; Panel on Treatment of HIV-Infected Pregnant Women
and Prevention of Perinatal Transmission, 2014).
Etravirine is a second generation NNRTI that was approved
by the US Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) in 2008 for use in
treatment-experienced patients with human immunodeficiency
virus type 1 (HIV-1). Etravirine is less susceptible to resistance
with activity against 55 of 65 HIV-1 strains with single point
mutation resistance to other NNRTIs (Product information,
2014). As such, etravirine holds an important place in the
treatment of resistant HIV-1 strains. The recommended dose
of etravirine in non-pregnant adults is 200mg twice-daily.
Etravirine is 99.9% protein bound and is a substrate for
CYP2C19, CYP2C9, and CYP3A4 (Product information, 2014).
CYP3A4 and CYP2C9 activity increases during pregnancy while
CYP2C19 activity is inhibited (Anderson, 2005; Ke et al., 2014).
To date, etravirine studies in pregnancy have been limited to a
small phase IIIb clinical trial and several case studies (Furco et al.,
2009; Jaworsky et al., 2010; Izurieta et al., 2011; Calcagno et al.,
2013; Shust et al., 2014; Ramgopal et al., 2016).
The primary objective of this study was to describe etravirine
pharmacokinetics in HIV-infected pregnant women receiving
standard adult doses and to compare 2nd and 3rd trimester
etravirine exposure to postpartum. A secondary objective of this
study was to describe transplacental passage of etravirine with
cord blood to maternal plasma ratios at delivery. This study
represents a collaboration between The International Maternal
Pediatric and Adolescent AIDS Clinical Trials (IMPAACT)
Network (P1026s protocol) and the “Pharmacokinetics of Newly
Developed Antiretroviral Agents in HIV-infected Pregnant
Women” (PANNA) Network.
METHODS
Study Population and Design
The IMPAACT protocol P1026s, “Pharmacokinetic Properties of
Antiretroviral Drugs during Pregnancy,” enrolled subjects from
sites in the Americas and is registered at ClinicalTrials.gov under
NCT00042289. The PANNA study enrolled subjects from sites
in Europe and is registered under NCT00825929. Both studies
are ongoing non-randomized, open-label, parallel-group, multi-
center phase-IV prospective studies in HIV-infected pregnant
women.
These studies recruited pregnant HIV-infected women
receiving etravirine prescribed as part of clinical care. Maternal
inclusion criteria were pregnancy, two-sample confirmation
of HIV-infection status, use of etravirine 200mg twice-daily,
2-week stability on a combination ART regimen, and intention
to continue ART treatment through 6–12 weeks postpartum.
Maternal exclusion criteria were multiple gestations, a clinical or
laboratory toxicity that would likely require changing medication
during the study period, and the use of specific medications
known to interfere with etravirine disposition. Subjects were
enrolled as early as the 2nd or 3rd trimester with the expectation
to complete all subsequent sampling time points.
Each study site received ethical and local institutional review
board approval. All subjects gave informed consent prior to study
participation. Medications were not furnished through this study
but were provided by each subject’s clinical care providers by
prescription. Pharmacokinetic sampling was performed during
the second trimester if possible, third trimester, and postpartum.
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In P1026s, samples were assayed in real time and results
reported to each study participant and her clinician. Participant
and clinician were also notified if etravirine pharmacokinetic
exposure was subtherapeutic, set at the 10th percentile AUC0–12
for non-pregnant adults, to make informed dose adjustments if
deemed necessary by the clinical care provider.
Clinical and Laboratory Monitoring
Each site visit for maternal plasma sampling includedmonitoring
of HIV-1 RNA, CD4+ lymphocyte cell count, hematology,
and serum biochemistry. The lower limit of detection for
HIV-1 RNA assays performed locally ranged from 20 to 400
copies/mL. A physical exam, history of concomitant medications
and perinatal adherence questionnaire were also collected at
each visit. All infants received physical examinations after birth
while laboratory evaluations were only performed if clinically
indicated. Clinical and laboratory toxicities were assessed
through medical histories, physical examinations and laboratory
testing on each pharmacokinetic sampling day and at delivery.
Adverse events were reported at each study visit and toxicity
management was determined by each participant’s clinician.
Sample Collection
Samples were collected over 12 h for pharmacokinetic evaluation
in the second trimester (20–28 weeks gestation), third trimester
(30–38 weeks gestation), and between 3 and 12 weeks following
delivery asmaternal physiological conditions generally normalize
to non-pregnant adult conditions within 6 weeks postpartum.
Cardiac output, heart rate, and stroke volume normalize within
24–72 h postpartum while respiratory parameters normalize
within 6–12 weeks postpartum to non-pregnant adult levels
(Datta et al., 2010). CYP1A2 enzymes appear to normalize to
non-pregnant adult levels of activity by 4 weeks postpartum. The
time-course of normalization following pregnancy is unknown
for other CYP450 enzymes (Anderson, 2005). Requirements
included etravirine dosing after meals, adherence for 2 weeks
prior to pharmacokinetic sampling and consistent dosing
times for the 3 days prior to pharmacokinetic sampling. On
sampling days the pre-dose sample was drawn and etravirine
was administered under observation at a time consistent with
previous doses. Serial blood collection was drawn by intravenous
catheter from an arm vein at pre-dose, 1, 2, 4, 6, 8, and 12 h
post-dose with additional time points at 0.5 and 3 h for PANNA
subjects. At delivery, one maternal plasma sample and one
umbilical cord blood sample were drawn after cord clamping.
Etravirine Concentration Assays
Etravirine concentration assays for IMPAACT samples were
analyzed at the Antiviral Pharmacology Laboratory at the
University of Nebraska Medical Center by validated reversed-
phase ultra performance liquid chromatography (UPLC). The
lower limit of quantification was 0.020 mcg/mL. The linear
fit detection ranges in plasma were from 0.020 to 20 mcg/mL.
Validation results displayed a greatest mean inter-assay percent
deviation of 2.6% with corresponding precision (within day,
coefficient of variation) of 3.5%. The greatest mean intra-assay
percent deviation was −15% and <3.8% at the lower limit of
quantitation (LLOQ) and above the LLOQ, respectively, with
a corresponding precision value (within day, coefficient of
variation) of 3.9%. Concentration assays for PANNA samples
were analyzed at the Radboud university medical center,
Nijmegen, The Netherlands by UPLC. The lower limit of
quantification was 0.026 mcg/mL. The linear calibration ranges
in plasma were from 0.026 to 15.78 mcg/mL. Validation results
displayed an accuracy of the Quality Control samples of 105,
104, and 100% at the plasma concentrations 0.37, 1.48, and
9.25 mcg/mL with corresponding precision values (within
day, coefficient of variation) of 2.0, 2.3, and 0.3%, respectively.
Both laboratories adhere to Clinical Laboratory Improvement
Amendments (CLIA) and perform standardized interlaboratory
testing though the AIDS Clinical Trial Group (ACTG)
clinical pharmacology quality assurance and quality control
program.
Pharmacokinetic Analyses
Etravirine maximum, minimum, and last plasma concentrations
(Cmax, Cmin, Clast) along with corresponding time points (tmax,
tmin) were observed directly. Area under the concentration vs.
time curve from time 0 to 12 h post-dose (AUC0–12) was
estimated with the trapezoidal rule. The half-life (t1/2) was
calculated as 0.693/λz where λz is the elimination constant
derived by the terminal slope of the log concentration vs.
time curve. Apparent oral clearance (CL/F) from plasma
was calculated as dose divided by AUC0–12. Undetectable
concentrations of etravirine were set at half the lower limit of
quantification to calculate summary statistics. The IMPAACT
protocol compared real time etravirine pharmacokinetic data
with those from historical controls reported in the literature.
Median trough concentrations of etravirine in non-pregnant
adult studies were 0.25 mcg/mL. The 50th percentile AUC0–12
in non-pregnant adult studies was 4.2mcg∗h/mL and the
P1026s study’s minimal exposure cut-off was the 10th percentile
AUC0–12 of 2.5 mcg∗h/mL to ensure treatment efficacy (Boffito
et al., 2007). The half maximal effective concentration (EC50)
of etravirine is 0.004 mcg/mL against wild-type HIV-1 (Product
information, 2014).
Statistical Analyses
The primary objective of this study was to compare
pharmacokinetic parameters in pregnant HIV-infected women
with paired postpartum data. Paired two-tailed Wilcoxon
signed rank tests (α = 0.05) were employed to compare
pharmacokinetic parameters in pregnant and non-pregnant
women. A two-tailed Mann–Whitney U-test was used to
compare pharmacokinetic parameters between subjects with
and subjects without concomitant use of a ritonavir-boosted
protease inhibitor with a two-sided p < 0.05. Statistical analysis
was performed with Stata Statistical Software 2013, graphs
were constructed using SlideWrite Plus 7.01 and tables were
constructed using Microsoft Excel 2010.
RESULTS
Subject Characteristics
Fifteen pregnant women taking etravirine 200mg twice daily
enrolled in this study. Data were available for five subjects in the
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2nd trimester. In the 3rd trimester, two womenwere lost to follow
up and ten additional women enrolled in the study (n = 13).
Postpartum data were available for one subject that began in the
2nd trimester and seven subjects that began in the 3rd trimester;
five subjects were lost to follow up after the 2nd trimester (n= 8).
Paired data were available for eight women that underwent
sampling in the 3rd trimester and postpartum. Cord/delivery
samples data were available for six mother-infant pairs. Subject
demographic and clinical characteristics are summarized in
Table 1. Among the 13 women available to follow-up, there were
13 live born infants for which data were available and the median
(range) birth weight was 3205 g (2620–3800).
Etravirine Pharmacokinetics
High inter-subject variability in etravirine pharmacokinetics was
observed. Etravirine CL/F was significantly lower in the 3rd
trimester of pregnancy compared to paired postpartum data
with a median CL/F reduction of 52% (p = 0.0251). Median
(range) etravirine CL/F during the 2nd trimester, 3rd trimester,
and postpartum periods were 44 L/h (19–59), 24 L/h (6–74), and
38 L/h (12–95), respectively, (Figure 1). Etravirinemaximum and
12-h concentrations were significantly higher in 3rd trimester
of pregnancy compared to paired postpartum data with median
elevations of 39 and 36%, respectively (p = 0.036, p = 0.036).
During the 2nd trimester, 3rd trimester and postpartum periods,
TABLE 1 | Subject demographics.
RACE/ETHNICITY
Black non-hispanic 7 (46.7%)
Hispanic 7 (46.7%)
Other 1 (6.7%)
Age at 3rd trimester (years) 25.6 (19.5–42.66)
Weight at 3rd trimester visit (kg) 76.6 (48–101.5)
Gestational age at 3rd trimester visit (weeks) 33.7 (30.3–36.7)
Weeks after delivery at postpartum PK visit 5.9 (3–8.4)
OTHER ANTIRETROVIRALS
Raltegravir 9 (60%)
Darunavir, ritonavir 6 (40%)
Truvada (emtricitabine, tenofovir) 4 (27%)
Kaletra (lopinavir, ritonavir) 3 (20%)
Combivir (lamivudine, zidovudine) 2 (13%)
Maraviroc 2 (13%)
Duration of etravirine therapy at 3rd trimester visit (weeks) 12.7 (4.6–91.6)
HIV-1 RNA AT DELIVERY
<50 copies/mL 9 (75%)
<400 copies/mL 10 (83%)
CD4 at delivery 420 (107–610)
Infant gestational age at birth (weeks) 38.6 (36–41.7)
Infant weight at birth (g) 3205 (2620–3800)
Infant length at birth (cm) 50 (45–52)
INFECTION STATUS
Negative based on best available data 13 (100%)
N = 15 for pregnant HIV-infected women and n = 13 for infants. Data are represented as
n (%) or median (range).
median (range) etravirine Cmax were 0.70mcg/mL (0.44–1.05),
1.01mcg/mL (0.26–3.47), and 0.63mcg/mL (0.30–1.60) and C12
were 0.36mcg/mL (0.08–0.75), 0.48mcg/mL (0.08–1.94), and
0.38mcg/mL (0.07–1.14; Figures 2, 3).
A trend in increased etravirine AUC0–12 in the third trimester
compared to postpartum was seen however, the difference
did not reach statistical significance (p = 0.0684). Median
(range) etravirine AUC0–12 during the 2nd trimester, 3rd
trimester, and postpartum periods were 4.5mcg∗h/mL (3.4–
10.7), 8.3mcg∗h/mL (2.7–31.0), and 5.3mcg∗h/mL (2.1–16.4),
respectively. The frequency of subjects meeting the estimated
AUC0–12 10th percentile (2.5mcg∗h/mL) from non-pregnant
historical controls was 5/5 (100%) subjects in the 2nd trimester,
13/13 (100%) subjects in the 3rd trimester, and 7/8 (88%)
subjects postpartum. The frequency of subjects with AUC0–12
above the 90th percentile (5.86 mcg∗h/mL) estimated from
non-pregnant historical controls was 2/5 (40%) subjects in
the 2nd trimester, 10/13 (77%) subjects in the 3rd trimester,
and 3/8 (38%) subjects postpartum. The frequency of subjects
meeting the 10th or 90th percentile across time points was
not statistically significant (p = 0.310, p = 0.139). All other
pharmacokinetic parameters were similar between 2nd trimester,
3rd trimester, and postpartum (Table 2). Pre-dose concentrations
below the lower limit of detection were seen in one subject
in the 3rd trimester and in another subject postpartum.
These values suggest non-adherence but were still included in
analysis.
Third trimester exposure was compared between subjects with
and subjects without concomitant use of a protease inhibitor (PI)
boosted by ritonavir (n = 9, n = 4). Median (range) AUC0–12-
values were 5.6mcg∗h/mL (2.7–11) without a boosted PI and 9.2
mcg∗h/mL (5–31) with a boosted PI (p= 0.182). Median (range)
CL/F-values were 36.9 L/h (18.2–74.1) without a boosted PI and
21.7 L/h (6.5–40) with a boosted PI (p = 0.162). Median (range)
Cmin-values were 0.30 mcg/mL (0–0.632) without a boosted PI
and 0.57mcg/mL (0.28–1.94) with a boosted PI (p = 0.165).
Etravirine exposure tended to increase and CL/F to decrease
with protease inhibitor use, however, these differences were not
statistically significant due to small subject populations.
Maternal plasma samples at delivery and umbilical cord
blood samples were collected from six subjects (Table 3). Median
(range) etravirine concentrations were 0.22mcg/mL (0.05–2.89)
in umbilical cord blood and 0.38mcg/mL (0.11–0.68) inmaternal
plasma. The median (range) ratio of cord blood to maternal
plasma concentration at delivery was 0.52 (range: 0.19–4.25). The
median (range) time between administration of the last antenatal
etravirine dose and delivery was 10.3 h (5.1–29.6).
Maternal and Infant Outcomes
In the course of this study, two women reported grade 3 adverse
events: fever and elevated glucose concentrations. In the 3rd
trimester, 10/13 (77%) of subjects had an HIV-1 RNA ≤ 50
copies/mL, and one subject had a viral load over 400 copies/mL.
At delivery, 9/12 (75%) maternal subjects had an HIV-1
RNA ≤ 50 copies/mL and two subjects had a viral load over 400
copies/mL (Table 1). At postpartum pharmacokinetic sampling,
6/7 (86%) maternal subjects achieved an HIV-1 RNA ≤ 50
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FIGURE 1 | IMPAACT subjects are represented in blue and PANNA
subjects are represented in green. (A) Paired AUC0–12 data in 2nd
trimester, 3rd trimester, and postpartum. (B) Paired C12 data in 2nd trimester,
3rd trimester, and postpartum. (C) Paired CL/F data in 2nd trimester, 3rd
trimester, and postpartum.
copies/mL. HIV-RNA testing results were not available within the
study window from 1 subject in the third trimester and 1 subject
postpartum.
FIGURE 2 | Median etravirine (ETV) concentration-time curves during
the 2nd trimester, 3rd trimester, and postpartum on 200mg twice-daily
dosing. Non-pregnant adult reference line is seen in solid line (Boffito et al.,
2007).
Data were available for 13 study infants. Infants were born
at a median of 38.6 weeks of gestation (range: 36–41.7) with
a median birth weight of 3205 g (range: 2620–3800). Three
infants had congenital anomalies: skin tag on ear, bilateral
double 5th toe, and patent foramen ovale with right to left
shunt and right ventricular hypertrophy. Four infants had Grade
3 or 4 laboratory abnormalities: glucose (n = 1), potassium
(n = 1), and absolute neutrophil count (n = 3). The patent
foramen ovale, ventricular hypertrophy, and abnormal glucose
were in the same infant. Patent foramen ovale is an abnormality
related to the physiological changes at birth therefore, the
maternal subject’s etravirine exposure was excluded from the
following “abnormality” grouping. Among mothers of infants
with anomalies, two women used etravirine prior to pregnancy,
one woman began etravirine use in the first trimester, and one
women began use in the second trimester of pregnancy. In
the 2nd trimester, mothers of infants with anomalies had an
average etravirine AUC0–12 of 9.5mcg∗h/mL (n = 2) compared
to an AUC0–12 of 4.0 mcg∗h/mL (n = 3) for mothers of infants
without anomalies. In the 3rd trimester, mothers of infants
with anomalies had a median (range) etravirine AUC0–12 of
7.45mcg∗h/mL (6.5–11.0, n = 4) compared to an AUC0–12 of
9.6 mcg∗h/mL (2.7–31.0, n = 9) for mothers of infants without
anomalies. Cord blood to maternal plasma ratios were 0.48
(n = 2) in infants with anomalies compared to 0.52 (0.2–4.3,
n= 5) in infants without anomalies. All (100%) infants were HIV
negative based on best available data.
DISCUSSION
Maintaining therapeutic antiretroviral exposure during
pregnancy is crucial for maternal health outcomes and reducing
perinatal transmission of HIV. An etravirine AUC0–12 below
the 10th percentile (2.5 mcg∗h/mL) of non-pregnant adults
was designated the pharmacokinetic target and 100% of
pregnant subjects and 89% of postpartum subjects met this
Frontiers in Pharmacology | www.frontiersin.org 5 August 2016 | Volume 7 | Article 239
Mulligan et al. Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
FIGURE 3 | (A) Etravirine (ETV) concentration-time curves during the 2nd
trimester following 200mg twice-daily dosing, (B) Etravirine (ETV)
concentration-time curves during the 3rd trimester following 200mg
twice-daily dosing, (C) Etravirine (ETV) concentration-time curves postpartum
following 200mg twice-daily dosing.
target (Boffito et al., 2007). Furthermore, C12 in all subjects and
gestational time points exceeded the in vitro etravirine EC50
for wild type HIV-1 (0.004mcg/mL) by one to three orders of
magnitude (Product information, 2014). These findings suggest
that standard etravirine dosage for non-pregnant adults, 200mg
twice-daily, provides sufficient exposure in pregnancy. Ten
(77%) subjects achieved undetectable HIV-1 RNA levels (≤ 50
copies/mL) at delivery. Among subjects that were not lost to
follow up, seven (88%) subjects had undetectable HIV-1 RNA
levels at postpartum pharmacokinetic sampling.
This study found that etravirine apparent oral clearance was
significantly reduced by 52% in the 3rd trimester of pregnancy
compared to paired postpartum data. The maximum and 12-h
plasma concentrations of etravirine were significantly increased
by 39 and 36% in the 3rd trimester compared to paired
postpartum data. Though not significant, a trend was seen for
elevated AUC0–12 in the 3rd trimester compared to postpartum.
It is likely this finding did not reach statistical significance
due to the small numbers of paired data (n = 9). During
the third trimester, 11 (85%) subjects had an AUC0–12 above
the estimated 90th percentile (5.86mcg∗h/mL) of historical
non-pregnant adult controls (Boffito et al., 2007). Etravirine
exposure appears to be increased in the 3rd trimester of
pregnancy.
Other assessments of etravirine pharmacokinetics in pregnant
HIV-infected women include two case studies, a case series of
data from four women and a presentation of data from a phase
IIIb pharmacokinetic study of 15 pregnant women. In the case
series of four pregnant patients, observed medians (ranges) in
the 3rd trimester were: AUC0–12 of 4.5mcg∗h/mL (3.0–8.9), C0
of 0.41 mcg/mL (0.15–0.90), Tmax of 3 h, Cmax of 0.69mcg/mL
(0.45–1.15), and CL/F of 44.3 L/h (22.6–65.8; Izurieta et al.,
2011). In comparison to this study, the case series observed
lower AUC0–12 and Cmax-values, comparable Tmax-values, and
higher C0 and CL/F-values during pregnancy; all parameters
fell within one standard deviation of this study’s findings. The
case series participants were generally a decade older than this
study’s subjects. In one case study, a 29 week multigestational
pregnancy had a C0 of 0.90mcg/mL, Tmax of 6 h, and a Cmax of
1.21mcg/mL (Furco et al., 2009). It is difficult to make a direct
comparison of multi-gestational pregnancy to single-gestational
pregnancy. Data from the phase IIIb trial of 15 pregnant women
was comparable to our findings with mean AUC0–12-values of
6.6± 2.8, 6.8± 1.5, and 5.0± 2.5mcg∗h/mL in the 2nd trimester,
3rd trimester, and postpartum, respectively. Subjects were older
than in this study with a median (range) of 26 years (20–34)
and 73% of subjects were black (Ramgopal et al., 2016). The
gender, race and clinical experience (GRACE) trial has shown
a direct relationship between age and etravirine exposure but
no significant differences across race in non-pregnant adults
(Kakuda et al., 2012). Phase III trials and a pharmacogenetic-
based population pharmacokinetic study have identified high
intersubject variability in etravirine exposure in non-pregnant
adults with 16% of variability attributed to genetics (Kakuda et al.,
2010; Lubomirov et al., 2013; Ramgopal et al., 2016).
A case study, a case series of data from 4 women and the
pharmacokinetic study of 15 pregnant women also reported data
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TABLE 2 | Etravirine pharmacokinetic parameters.
Parameter 2nd Trimester 3rd Trimester Postpartum Geometric mean Historical
n = 5 n = 13 n = 8 3rd/Post Ratio Control
AUC0–12 (mcg*h/mL) 4.5 (3.4–10.7) 8.3 (2.7–31.0) 5.3 (2.1–16.4) 1.34 6.03 (Schöller-Gyüre et al., 2009)
C0 (mcg/mL) 0.26 (0.07–1.05) 0.60 (<0.005–2.64) 0.43 (<0.005–1.21) 2.03 0.28 (0.10–0.85) (Boffito et al., 2007)
Cmax (mcg/mL) 0.70 (0.44–1.05) 1.01 (0.26–3.47)* 0.63 (0.30–1.60) 1.34 0.44 (0.20–1.50) (Boffito et al., 2007)
Tmax (h) 2 (0–8) 4 (2–6) 4 (1–4) 1.10 4 (1–6) (Schöller-Gyüre et al., 2009)
C12 (mcg/mL) 0.36 (0.08–0.75) 0.48 (0.08–1.94)* 0.38 (0.07–1.14) 1.41 0.47 (Schöller-Gyüre et al., 2009)
Cmin (mcg/mL) 0.25 (0.07–0.75) 0.45 (<0.005–1.94) 0.38 (<0.005–1.14) 1.94 0.24 (0.09–0.73) (Boffito et al., 2007)
CL/F (L/h) 44 (19–59) 24 (6–74)* 38 (12–95) 0.75 †
AUC0−12, area under the concentration vs. time curve from 0 to 12 h; C0, pre-dose concentration; Cmax , maximum concentration; Tmax , time at which maximum concentration occurred;
C12, 12 h post-dose concentration; Cmin, minimum observed concentration; Tmin, time at which minimum concentration occurred; CL/F, oral clearance. Data are represented as median
(range). *p < 0.05 for 3rd trimester vs. postpartum values using Wilcoxon signed-rank test. For other pharmacokinetic parameters in the 3rd trimester and postpartum, n = 13 and
8, respectively. Historical data AUC0–12 mean was 4.2 mcg*h/mL among non-pregnant adults (Boffito et al., 2007) and 6.03 mcg*h/mL among non-pregnant women (Schöller-Gyüre
et al., 2009).
†
Describes data which was absent in referenced study.
TABLE 3 | Placental passage (n = 7).
Parameter Median (range)
Cord blood concentration (mcg/mL) 0.22 (0.05–2.89)
Maternal plasma concentration (mcg/mL) 0.38 (0.11–0.68)
Cord blood/maternal plasma ratio 0.52 (0.19–4.25)
Cord blood and maternal plasma concentrations were collected after cord clamping.
on the transplacental passage of etravirine. The median (range)
cord blood to maternal plasma ratio of etravirine in this study
was 0.52 (0.19–4.25, n= 6) and higher than in 3 previous studies:
0.32 (0.19–0.63), 0.51, and 0.33 (Izurieta et al., 2011; Calcagno
et al., 2013; Ramgopal et al., 2016).
The DUET-I and DUET-II clinical trials of etravirine were
administered with boosted darunavir (DRV/r) and several
subsequent studies have evaluated etravirine use with DRV/r in
the non-pregnant adult population (Schöller-Gyüre et al., 2007;
Kakuda et al., 2008, 2010; Katlama et al., 2010; Lubomirov et al.,
2013). Concomitant DRV/r significantly increases etravirine
apparent oral clearance by 40% in the non-pregnant adult
population (Schöller-Gyüre et al., 2007; Kakuda et al., 2010;
Lubomirov et al., 2013). Two studies have also analyzed
concomitant use of etravirine with boosted lopinavir (LPV/r;
Lubomirov et al., 2013; Schöller-Gyüre et al., 2013). Concomitant
LPV/r also increases etravirine apparent oral clearance in the
non-pregnant adult population but not significantly (Lubomirov
et al., 2013; Kakuda et al., 2010; Schöller-Gyüre et al., 2007). For
this reason, we compared 3rd trimester etravirine concentrations
between patients with (n = 9) and without (n = 4) use of
boosted protease inhibitors (6 with DRV/r, 3 with LPV/r).
No significant differences were seen in 3rd trimester etravirine
AUC0–12, CL/F and Cmin but our small sample size limits the
power of this analysis. These findings oppose previous study
findings in non-pregnant adults. Due to our study’s small subject
population and high intersubject variability, more data are
needed to elucidate the effect of DRV/r or LPV/r on etravirine
pharmacokinetics in the pregnant population. It is possible that
the influence of pregnancy on increasing etravirine exposure
may outweigh DRV/r or LPV/r effects on decreased etravirine
exposure.
Increased etravirine exposure during the 3rd trimester of
pregnancy is a unique finding among antiretroviral drugs. This
finding is likely due to the unique metabolism of etravirine by
CYP3A4, CYP2C9, and CYP2C19 (Product information, 2014).
Many antiretroviral drugs are metabolized by CYP3A4, and
show evidence of lowered exposure in pregnancy (Panel on
Treatment of HIV-Infected Pregnant Women and Prevention
of Perinatal Transmission, 2014). In contrast, CYP2C9 and
CYP2C19 contributes to the metabolism of few antiretrovirals.
Metabolite identification experiments identified CYP2C19 as the
primarymetabolizer of etravirine yielding twomajor metabolites.
The same study found CYP3A4 and CYP2C9 form several minor
metabolites (Yanakakis and Bumpus, 2012). During pregnancy,
enzyme expression of CYP2C19 is suppressed while CYP3A4
and CYP2C9 are induced (Anderson, 2005; Ke et al., 2014). Our
findings of decreased etravirine apparent oral clearance in the 3rd
trimester of pregnancy is consistent with reduction in CYP2C19
expression in pregnancy resulting in higher etravirine plasma
concentrations. Both CYP2C19 and CYP2C9 have well-described
genetic variations associated with impaired drug metabolism
which accounts for some interpatient variability (Lubomirov
et al., 2013). Subjects of this study were not genotyped.
Increases in total drug exposure typically raise concerns
about toxicity. Furthermore, etravirine is 99.9% protein bound,
primarily to albumin and alpha 1-acid glycoprotein (Product
information, 2014). In pregnancy, increases in several hormones
compete for protein binding while an increase in volume has a
dilutional effect on plasma proteins (Mirochnick and Capparelli,
2004). Very small losses in the number of protein binding
sites is also a concern as this can significantly impact free-
drug concentrations and the risk of toxicity. While we did not
measure free concentration of etravirine in plasma, etravirine
was generally well-tolerated in our subjects with only two reports
of grade 3 or 4 adverse events. A dose-ranging study with
etravirine 400, 800, and 1200mg twice-daily found no dose
relationship to adverse event frequency or severity (Montaner
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et al., 2008). Combined with a mild adverse event profile,
primarily rash and nausea with rare hypersensitivity reactions,
multiple dose-ranging trials have stated that no dose adjustment
is necessary in elevated etravirine exposure (Kakuda et al.,
2007, 2008; Montaner et al., 2008). We identified moderate
placental transfer of etravirine to the fetus with a 0.52 cord
blood to maternal ratio, so elevated maternal etravirine plasma
concentrations could also lead to high fetal concentrations (Panel
on Treatment of HIV-Infected Pregnant Women and Prevention
of Perinatal Transmission, 2014). High fetal concentrations may
be beneficial in prophylaxis against HIV-infection or may cause
toxicities in the infant. Thirteen (100%) of this study’s infants
were HIV negative based on best available data. This study
identified three infants (23%) with congenital anomalies and
four (31%) with grade 3 or 4 laboratory abnormalities. Aside
from case studies, no published literature describes etravirine
exposure in infants. While elevated etravirine concentrations do
not require dose adjustments for maternal health, it remains
unclear if standard adult dosing of etravirine in pregnancy will
have significant clinical impact on the fetus. The antiretroviral
pregnancy registry interim report described 1/54 birth defects in
54 first trimester etravirine exposures between January 1st 1989
through January 31st 2015. This is below the background rate
of congenital anomalies (The Antiretroviral Pregnancy Registry
Steering Committee, 2015). Three of the five women with infants
displaying congenital or laboratory anomalies in this study were
exposed to etravirine in the first trimester of pregnancy.
Several study limitations must be considered. Opportunistic
recruitment of pregnant women already receiving etravirine
as part of their clinical care with 2 week stability on the
combination ART regimen excludes early signs of toxicity,
intolerance, virologic failure, and other reasons for medication
discontinuation. This exclusion introduces bias toward pregnant
women that tolerated and responded to etravirine therapy.
Medication adherence and dosing relative to meals were self-
reported. Since food impacts etravirine absorption, unidentified
poor adherence, or recall bias may have added greater variability
to our findings (Lubomirov et al., 2013). Postpartum sampling
occurred between 3 and 12 weeks following delivery. During
the postpartum period, physiological changes occur rapidly and
our postpartum pharmacokinetic data has high variability as
compared to other time points. A majority of study participants
were black or Hispanic in their twenties. Studies have shown
a relationship between age and etravirine exposure but no
significant differences across race (Schöller-Gyüre et al., 2009;
Kakuda et al., 2010; Lubomirov et al., 2013). Subjects enrolled at
various stages of pregnancy and duration of etravirine use ranged
from 4.6 to 91.6 weeks at the time of third trimester sampling.
However, phase III trials found that etravirine reaches steady-
state exposure by 4 weeks in non-pregnant adults (Kakuda et al.,
2010).
In summary, the 200mg twice-daily dosing of etravirine
recommended for non-pregnant adults achieves elevated
exposure in the 3rd trimester of pregnancy. Previous studies have
shown no relationship between etravirine exposure and adverse
event incidence or severity suggesting no dose adjustment is
necessary for maternal health. However, it remains unclear how
elevated maternal etravirine concentrations in the 3rd trimester
will impact infant health. Close monitoring of mother and infant
outcomes is warranted.
AUTHOR CONTRIBUTIONS
All co-authors reviewed, revised for content, and approved
this article. Additionally, AC, JM, AS, GT, CH, CF, and MV
substantially contributed to data acquisition. NM, SS, BB, AC,
JW, EC, AS, ES, NC, MM, and DB substantially contributed
to conception and design of study, data analysis and data
interpretation.
FUNDING
Overall support for the International Maternal Pediatric
Adolescent AIDS Clinical Trials Group (IMPAACT) was
provided by the National Institute of Allergy and Infectious
Diseases (NIAID) of the National Institutes of Health (NIH)
under Award Numbers UM1AI068632 (IMPAACT LOC),
UM1AI068616 (IMPAACT SDMC) and UM1AI106716
(IMPAACT LC), with co-funding from the Eunice Kennedy
Shriver National Institute of Child Health and Human
Development (NICHD) and the National Institute of Mental
Health (NIMH). The content is solely the responsibility of the
authors and does not necessarily represent the official views
of the NIH. Overall support for the “Pharmacokinetics of
newly developed antiretroviral agents in HIV-infected pregnant
women (PANNA)” network is financially supported by the
“European AIDS Treatment Network (NEAT)” under the
European Commission, DG Research, 6th Framework program,
contract LSHP-CT-2006-037570 and the “Pediatric European
Network for Treatment of AIDS (PENTA)” under the European
Commission, DG Research, 5th Framework program, contract
QLK2-CT-2000-00150 and 6th Framework program, contract
LSHP-CT-2006-018865, with co-funding from Merck Sharp &
Dohme Corp, Bristol Myers Squibb, Janssen Research and ViiV
Healthcare.
ACKNOWLEDGMENTS
We thank the study participants and their families. We thank
TimMykris for quantitation of etravirine plasma concentrations.
In addition to the authors, members of the IMPAACT P1026s
protocol team include Francesca Aweeka, Michael Basar, Emily
Barr, Mark Byroads, Nantasak Chotivanich, Lisa M. Frenkel,
Kathy George, Elizabeth Hawkins, Adriane Hernandez, Amy
Jennings, Rita Patel, and Pra-ornsuda Sukrakanchana. We also
thank the following investigators and staff at the enrolling sites:
Andrea Antinori, IRCSS, Roma, Italy; Ineke van der Ende,
Erasmus MC Rotterdam, The Netherlands; Gerd Faetkenheuer,
University of Cologne, Cologne, Germany; Carlo Giaquinto,
University of Padua, Italy; Yvonne Gilleece, Brighton and
Sussex University Hospitals NHS Trust, Brighton, UK; Andrea
Gingelmaier, Klinikum der Universität München, Frauenklinik
Innenstadt, München, Germany; Annette Haberl–Johann
Frontiers in Pharmacology | www.frontiersin.org 8 August 2016 | Volume 7 | Article 239
Mulligan et al. Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
Wolfgang Goethe-Universität, Frankfurt am Main, Germany;
David Hawkins–Chelsea & Westminster Hospital, London,
UK; Jelena Ivanovic, IRCSS, Roma, Italy; Kabamba Kabeya–
Saint-Pierre University Hospital, Brussels, Belgium; John
Lambert, Mater Misericordiae University Hospital Dublin,
Ireland; Fyona Lyons, St. James’s Hospital Dublin, Ireland;
Jeannine Nellen, Academisch Medisch Centrum, Amsterdam,
The Netherlands; Emanuelle Nicastri, MD, National Institute
for Infectious Diseases "L. Spallanzani,” Rome, Italy; Jürgen
Rockstroh and Caroline Schwarze-Zander, University of Bonn,
Germany; Annemiek de Ruiter, St. Thomas’ hospital, London,
UK; Tariq Sadiq, Institution for Infection and Immunity, St.
George’s, University of London, London, UK; André van der
Ven, Radboud University Medical Center, Nijmegen, The
Netherlands; Katharina Weizsäcker, Klinik für Geburtsmedizin;
Charité Universitätsmedizin, Berlin, Germany; Chris Wood,
North Middlesex Hospital, London, UK; Christoph Wyen,
University of Cologne, Cologne, Germany.
REFERENCES
Anderson, G. D. (2005). Pregnancy-induced changes in pharmacokinetics: a
mechanistic-based approach. Clin. Pharmacokinet. 44, 989–1008. doi: 10.21
65/00003088-200544100-00001
Boffito, M., Winston, A., Jackson, A., Fletcher, C., Pozniak, A., Nelson, M., et al.
(2007). Pharmacokinetics and antiretroviral response to darunavir/ritonavir
and etravirine combination in patients with high-level viral resistance. AIDS
21, 1449–1455. doi: 10.1097/QAD.0b013e3282170ab1
Calcagno, A., Trentini, L., Marinaro, L.,Montrucchio, C., D’Avolio, A., Ghisetti, V.,
et al. (2013). Transplacental passage of etravirine andmaraviroc in a multidrug-
experienced HIV-infected woman failing on darunavir-based HAART in
late pregnancy. J. Antimicrob. Chemother. 68, 1938–1939. doi: 10.1093/jac/
dkt095
Colbers, A., Gingelmaier, A., van der Ende, M., Rijnders, B., and Burger, D.
(2014). Pharmacokinetics, safety and transplacental passage of rilpivirine in
pregnancy: two cases. AIDS 28, 288–290. doi: 10.1097/QAD.00000000000
00100
Datta, S., Segal, S., and Kodali, B. S. (2010). “Maternal physiological changes
during pregnancy, labor, and the postpartum period,” in Obstetric Anesthesia
Handbook, 5th Edn (New York, NY: Springer), 1–15.
Furco, A., Gosrani, B., Nicholas, S., Williams, A., Braithwaite, W., Pozniak,
A., et al. (2009). Successful use of darunavir, etravirine, enfuvirtide and
tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance.
AIDS 23, 434–435. doi: 10.1097/QAD.0b013e32832027d6
HIV/AIDS data and statistics (2013).HIV/AIDS Data and Statistics. Bethesda, MD:
World Health Organization. Available online at: http://www.who.int/hiv/data/
en/ (Accessed June 22, 2015).
HIV among pregnant women, infants, and children in the United States
(2012). HIV among Pregnant Women, Infants, and Children in the United
States. Atlanta, GA: Center for Disease Control, Division of HIV/AIDS
Prevention. Available online at: http://www.cdc.gov/hiv/pdf/risk_WIC.pdf
(Accessed September 3, 2015).
Izurieta, P., Kakuda, T. N., Feys, C., and Witek, J. (2011). Safety and
pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med.
12, 257–258. doi: 10.1111/j.1468-1293.2010.00874.x
Jaworsky, D., Thompson, C., Yudin, M. H., Bitnun, A., Brophy, J., Samson, L.,
et al. (2010). Use of newer antiretroviral agents, darunavir and etravirine with
or without raltegravir, in pregnancy: a report of two cases. Antivir Ther 15,
677–680. doi: 10.3851/IMP1558
Kakuda, T. N., Wade, J. R., Snoeck, E., Vis, P., Schöller-Gyüre, M.,
Peeters, M. P., et al. (2010). Pharmacokinetics and pharmacodynamics of
the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-
experienced HIV-1-infected patients. Clin. Pharmacol. Ther. 88, 695–703. doi:
10.1038/clpt.2010.181
Kakuda, T., Peeters, M., Corbett, C., De Smedt, G., Sinha, R., Leopold,
L., et al. (2008). “Pharmacokinetics (PK) and pharmacodynamics (PD)
of etravirine (ETR) in treatment-experienced HIV-1 infected patients:
pooled 48-week results of DUET-1 and DUET-2 [abstract no. H-4056],”
in 48th Interscience Conference on Antimicrobial Agents and Chemotherapy
(Washington, DC).
Kakuda, T. N., Schöller-Gyüre, M., Peeters, M., Vingerhoets, J., Corbett, C.,
Woodfall, B. J., et al. (2007). “Pharmacokinetics and pharmacodynamics of
TMC125 in HIV-infected patients with non-nucleoside reverse transcriptase
inhibitor and protease inhibitor resistance: TMC125-C223 [abstract no. L-
131],” in 14th Conference on Retroviruses and Opportunistic Infections (Los
Angeles, CA), 25–28.
Kakuda, T., Sekar, V., Vis, P., Coate, B., Ryan, R., Anderson, D., et al. (2012).
Pharmacokinetics and pharmacodynamics of darunavir and etravirine in
HIV-1-infected, treatment-experienced patients in the Gender, Race, and
Clinical Experience (GRACE) trial. AIDS Res. Treat. 2012:186987. doi:
10.1155/2012/186987
Katlama, C., Clotet, B., Mills, A., Trottier, B., Molina, J. M., Grinsztejn, B., et al.
(2010). Efficacy and safety of etravirine at week 96 in treatment-experienced
HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir. Ther.
15, 1045–1052. doi: 10.3851/IMP1662
Ke, A. B., Nallani, S. C., Zhao, P., Rostami-Hodjegan, A., and Unadkat, J.
D. (2014). Expansion of a PBPK model to predict disposition in pregnant
women of drugs cleared via multiple CYP enzymes, including CYP2B6,
CYP2C9 and CYP2C19. Br. J. Clin. Pharmacol. 77, 554–570. doi: 10.1111/bcp.
12207
Lubomirov, R., Arab-Alameddine, M., Rotger, M., Fayet-Mello, A., Martinez,
R., Guidi, M., et al. (2013). Pharmacogenetics-based population
pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Pharmacogenet. Genomics 23, 9–18. doi: 10.1097/FPC.0b013e32835
ade82
Mirochnick,M., Best, B.M., and Clarke, D. F. (2010). Antiretroviral pharmacology:
special issues regarding pregnant women and neonates. Clin. Perinatol. 37,
907–927, xi. doi: 10.1016/j.clp.2010.08.006
Mirochnick, M., and Capparelli, E. (2004). Pharmacokinetics of antiretrovirals in
pregnant women. Clin. Pharmacokinet 43, 1071–1087. doi: 10.2165/00003088-
200443150-00002
Montaner, J., Yeni, P., Clumeck, N. N., Fätkenheuer, G., Gatell, J., Hay, P.,
et al. (2008). Safety, tolerability, and preliminary efficacy of 48 weeks of
etravirine therapy in a phase IIb dose-ranging study involving treatment-
experienced patients with HIV-1 infection. Clin. Infect. Dis. 47, 969–978. doi:
10.1086/591705
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of
Perinatal Transmission (2014). Recommendations for Use of Antiretroviral
Drugs in Pregnant HIV-1-Infected Women for Maternal Health and
Interventions to Reduce Perinatal HIV Transmission in the United
States. Bethesda, MD: National Institutes of Health. Available online at:
http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf (Accessed
June 22, 2015).
Product information (2014). Intelence (etravirine) Tablet. Titusville, NJ: Janssen
Pharmaceuticals, Inc.
Prevention of mother-to-child transmission (2015). Prevention of Mother-to-Child
Transmission. Bethesda, MD: World Health Organization. Available online at:
http://www.who.int/gho/hiv/epidemic_response/PMTCT_text/en/# (Accessed
June 22, 2015).
Ramgopal, M., Osiyemi, O., Zorrilla, C., Crauwels, H.M., Ryan, R., Brown, K., et al.
(2016). Pharmacokinetics of total and unbound etravirine in HIV-1- infected
pregnant women. J. Acquir. Immune Defic. Syndr. doi: 10.1097/QAI.00000000
00001068. [Epub ahead of print].
Schöller-Gyüre, M., Kakuda, T. N., Raoof, A., De Smedt, G., and Hoetelmans, R.
M. (2009). Clinical pharmacokinetics and pharmacodynamics of etravirine.
Clin. Pharmacokinet 48, 561–574. doi: 10.2165/10895940-000000000-
00000
Frontiers in Pharmacology | www.frontiersin.org 9 August 2016 | Volume 7 | Article 239
Mulligan et al. Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
Schöller-Gyüre, M., Kakuda, T. N., Sekar, V., Woodfall, B., De Smedt, G., Lefebvre,
E., et al. (2007). Pharmacokinetics of darunavir/ritonavir and TMC125
alone and coadministered in HIV-negative volunteers. Antivir. Ther. 12,
789–796.
Schöller-Gyüre, M., Kakuda, T. N., Witek, J., Akuma, S. H., De Smedt, G.,
Spittaels, K., et al. (2013). Steady-state pharmacokinetics of etravirine and
lopinavir/ritonavir melt extrusion formulation, alone and in combination,
in healthy HIV-negative volunteers. J. Clin. Pharmacol. 53, 202–210. doi:
10.1177/0091270012445205
Shust, G. F., Jao, J., Rodriguez-Caprio, G., Posada, R., Chen, K. T., Averitt, A.,
et al. (2014). Salvage regimens containing darunavir, etravirine, raltegravir,
or enfuvirtide in highly treatment-experienced perinatally infected pregnant
women. J. Pediatric Infect. Dis. Soc. 3, 246–250. doi: 10.1093/jpids/
pit019
The Antiretroviral Pregnancy Registry Steering Committee (2015). Antiretroviral
Pregnancy Registry International Interim Report for 1 January 1989 through 31
January 2015. Wilmington, NC: Registry Coordinating Center. Available online
at: http://www.apregistry.com (Accessed August 19, 2015).
Yanakakis, L. J., and Bumpus, N. N. (2012). Biotransformation of the
antiretroviral drug etravirine: metabolite identification, reaction phenotyping,
and characterization of autoinduction of cytochrome P450-dependent
metabolism. Drug Metab. Dispos. 40, 803–814. doi: 10.1124/dmd.111.044404
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Mulligan, Schalkwijk, Best, Colbers, Wang, Capparelli, Moltó,
Stek, Taylor, Smith, Hidalgo Tenorio, Chakhtoura, van Kasteren, Fletcher,
Mirochnick, Burger and on behalf of the PANNA Network and the IMPAACT
1026s Study Teams. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 10 August 2016 | Volume 7 | Article 239
